Search
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI). … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Synonyms: t-PA, t-plasminogen activatorDocetaxel
go.drugbank.com/drugs/DB01248ApprovedInvestigational[A259676] Compared to paclitaxel, docetaxel is two times more potent as an inhibitor of microtubule depolymerization. Docetaxel binds to microtubules but does not interact with dimeric tubulin. … [A259676,L46466] Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiometric ratio, allowing it to prevent cell division and promote to cell death.
Retapamulin
go.drugbank.com/drugs/DB01256ApprovedRetapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007.
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalIt is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of … tryptophan to 5-hydroxytryptophan via tryptophan hydroxylase.
Atenolol
go.drugbank.com/drugs/DB00335ApprovedInvestigationalLater they continued to be investigated for use in heart failure throughout the 1970-1980s. … Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.
Mixtures: NIFETEX-TR CAPSULE, ATENOLOL CO RATIO 100/25MGProducts: MIN-TTavaborole
go.drugbank.com/drugs/DB09041ApprovedTavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). … Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes
Idelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalBy inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and … co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.
Elafibranor
go.drugbank.com/drugs/DB05187ApprovedInvestigationalElafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist [A263833] that works to inhibit bile acid synthesis. … [L50773] The drug was also approved by the EMA on September 23, 2024.[L51878]
Levamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [A178117, A178123] Levamisole was withdrawn from the American market in 2000 due to its ability to cause serious adverse effects, including agranulocytosis.
Products: OBAT CACING NO.17 KAM CEK SANCefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigationalCefiderocol was granted designation as a Qualified Infectious Disease Product and granted priority review status by the FDA on November 14, 2019. … [A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase